Screen Shot 2022-08-09 at 9.56.50 AM

Fill out the form to download the booklet.

From the new FDA framework to the urgency of COVID-19, recent events have dramatically accelerated the use of RWE in regulatory decision-making. Now, life sciences organizations are investing heavily in analytics to generate RWE for regulatory submission.

This booklet compiles 12 recent cases where the regulatory decision for a new drug or label expansion was influenced by RWE. Download the booklet to find out:

  1. Background of drugs and reason for regulatory submission
  2. How RWE was used and what impact it had on the decision
  3. Regulatory approval and its impact on future decision-making